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http://www.ascpjournal.org/content/9/1/8RESEARCH Open AccessRandomized clinical trial of the effects of
screening and brief intervention for illicit drug
use: the life shift/shift gears study
Susan I Woodruff1*, John D Clapp2, Kimberly Eisenberg3, Cameron McCabe3, Melinda Hohman1, Audrey M Shillington4,
C Beth Sise5, Edward M Castillo6, Theodore C Chan6, Michael J Sise5 and Joey Gareri7Abstract
Background: Although screening, brief intervention, and referral to treatment (SBIRT) has shown promise for alcohol
use, relatively little is known about its effectiveness for adult illicit drug use. This randomized controlled trial assessed
the effectiveness of the SBIRT approach for outcomes related to drug use among patients visiting trauma and
emergency departments (EDs) at two large, urban hospitals.
Methods: A total of 700 ED patients who admitted using illegal drugs in the past 30 days were recruited, consented,
provided baseline measures of substance use and related problems measured with the Addiction Severity Index-Lite
(ASI-Lite), and then randomized to the Life Shift SBIRT intervention or to an attention-placebo control group focusing
on driving and traffic safety (Shift Gears). Both groups received a level of motivational intervention matched to their
condition and risk level by trained paraprofessional health educators. Separate measurement technicians conducted
face-to-face follow-ups at 6 months post-intervention and collected hair samples to confirm reports of abstinence from
drug use. The primary outcome measure of the study was past 30-day drug abstinence at 6 months post-intervention,
as self-reported on the ASI-Lite.
Results: Of 700 participants, 292 (42%) completed follow-up. There were no significant differences in self-reported
abstinence (12.5% vs. 12.0% , p = 0.88) for Life Shift and Shift Gears groups, respectively. When results of hair analyses
were applied, the abstinence rate was 7 percent for Life Shift and 2 percent for Shift Gears (p = .074). In an analysis in
which results were imputed (n = 694), there was no significant difference in the ASI-Lite drug use composite scores
(Life Shift +0.005 vs. Shift Gears +0.017, p = 0.12).
Conclusions: In this randomized controlled trial, there was no evidence of effectiveness of SBIRT on the primary drug
use outcome.
Trial registration: ClinicalTrials.gov NCT01683227.
Keywords: Screening and brief intervention, Drug use, Emergency department patientsBackground
The San Diego-Mexico border is one of the most active
drug smuggling corridors in the world. San Diego has
been designated as a High-Intensity Drug Trafficking
Area due to the large quantities of cocaine, heroin, and
methamphetamine that are transported to the County
from Mexico. Nearly two-thirds of women and more* Correspondence: swoodruff@mail.sdsu.edu
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reproduction in any medium, provided the orthan half of men arrested and booked into jail for crimes
in San Diego County in 2010 tested positive for illicit
drugs, such as marijuana, methamphetamine, cocaine, and
heroin [1]. It is estimated that the total economic cost of
alcohol and drug abuse in the region is more than $240
billion annually, with about $97 billion due to drug abuse
[2]. Patients who visit hospital emergency departments
(EDs) may be at particularly high risk for a variety of be-
havioral risk factors such as illicit substance use [3].
Screening, Brief Intervention, and Referral to Treat-
ment (SBIRT) is a comprehensive, integrated public healthral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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intervention services for substance use in general medical
care settings, including the ED [4,5]. These settings offer a
potential “teachable moment” because patients may have
perceptions of vulnerability about their health, regardless
of the reason for the visit, and therefore may be particu-
larly receptive to screening and counseling [6]. Unlike pri-
mary prevention that targets non-risk or low-risk users, or
treatment services for people already dependent, SBIRT
provides early intervention services targeted at individuals
who misuse alcohol or illicit drugs, but who may not be
dependent. Although individual program frameworks vary,
all SBIRT programs share two key components: screening
and intervention. Individuals who screen positive for alco-
hol or drug problems are provided with an appropriate
educational or therapeutic service. Most of those screen-
ing positive are categorized as relatively low risk and re-
ceive a brief intervention, consisting of a time-limited
motivational interview done on site that focuses on in-
creasing patient awareness of the risks of substance abuse,
feedback on normative use and safe limits, and eliciting
motivation to change [4]. Individuals at moderate- to se-
vere risk are provided brief intervention plus brief treat-
ment (e.g., six face-to-face counseling sessions) or referral
to specialty treatment for more intensive support [4].
Although the SBIRT approach has shown promise for
alcohol use [7-9], relatively little is known about its effect-
iveness for illicit drug use specifically [10]. An inter-
national study reported that brief intervention in primary
health-care settings was associated with reductions in self-
reported illicit substance use in several countries, with the
exception of the United States [11]. Madras and colleagues
[12] found a 68 percent reduction in self-reported illicit
drug use among those exposed to screening and brief
intervention services, although their study did not include
a control group. A randomized study of opioid and co-
caine users screened by peer interventionists during an ur-
gent care visit reported a salutary effect of screening and
brief intervention on drug use [13]. With the exception of
the Bernstein et al. study [13], methodological issues, such
as lack of biological confirmation of drug use, short
follow-up periods, lack of control groups, and the inability
to rule out reactivity to measurement, limit conclusions
about intervention effectiveness.
SBIRT is quickly becoming a recommended best prac-
tice in a variety of settings, especially in EDs and trauma
centers, and billing for SBIRT services is becoming easier
as more states activate billing codes. However, rigorous
research is needed before SBIRT for drug use is ready
for broad universal dissemination [14]. The present
study is one of the first rigorous studies to evaluate the
effectiveness of SBIRT for illegal drug use. This random-
ized controlled trial assessed the effectiveness of the
SBIRT approach for outcomes related to drug use amongpatients visiting EDs at two large, urban, acute-care hos-
pitals in Southern California.
Methods
Design overview
This study evaluated the effectiveness of SBIRT for drug
use and related factors for 700 multi-ethnic trauma and
ED patients using a two-group, randomized, repeated-
measures design. Self-reported drug use, biologically
validated drug use abstinence, health-care utilization,
medical and psychiatric problems, and alcohol use in the
drug-based intervention group were compared to that of
an attention-placebo control group that received equal
intervention in the areas of driving and traffic safety.
Three bilingual/bicultural health educators (HEs) re-
cruited participants who reported past 30-day illicit drug
use that was more severe than their alcohol use from
trauma units and the ED waiting areas of two large hos-
pitals (details regarding HE selection and training are
described in Eisenberg and Woodruff, 2013 [15]). Fol-
lowing consent procedures and standardized baseline as-
sessments, HEs randomly assigned participants to one of
the two conditions. The intervention group received
“Life Shift”, an SBIRT drug use intervention matched to
the participant’s drug risk level. The control group re-
ceived the same exposure to intervention in an unrelated
area—driving and traffic safety (“Shift Gears”) that was
matched to their driving/traffic risk level. Measurement
technicians (MTs)—separate from the interventionist
staff and blind to the participants’ assigned conditions—
conducted face-to-face, 6-month, follow-up visits and col-
lected the same outcome measures, as well as hair samples
for validating self-reported drug abstinence. Approvals
from the San Diego State University IRB and hospital IRBs
were obtained prior to contact with participants. Trial
registration with ClinicalTrials.gov was not completed
until all participants were enrolled and follow-up was
completed.
Participant enrollment
Participant enrollment and intervention was conducted
from April 2010 to June 2011 in the EDs and trauma
units of two large urban hospitals in Southern California.
HEs attempted to approach all capable adult patients, re-
gardless of the reason for the patient’s visit. Patients
under the age of 18, those with severely altered mental
status, those physically incapable of participating due to
severe illness or injury, those without any phone number
where they could be reached, and those unable to speak
English or Spanish were excluded from participation.
Further eligibility was then based on responses to two
pre-screen items that assessed any current (i.e., past
30 day) alcohol use and use of non-prescribed drugs.
The specific screening questions were: “How many times
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“How many times in the past 30 days have you used any
non-prescribed drugs?” Hair samples to confirm self-
reported drug use were not collected at baseline, as par-
ticipants were not expected to falsely report using drugs
[16]. Distracter items assessing nutrition, exercise, and
driving/traffic safety were asked so that potential partici-
pants did not guess the primary purpose of the study.
Those answering “0 times” to both the current use of al-
cohol and drug questions were verbally reinforced and
thanked for their interest. Those reporting alcohol use
only were given an alcohol use brochure that described
lower-risk drinking limits; were encouraged to seek fur-
ther assistance via the internet and community resources
for alcohol problems; and were thanked for their inter-
est. Those reporting illicit drug use were further consid-
ered for inclusion.
A sizable number of drug users were also users of al-
cohol, and depending on the severity of alcohol use, it
may pose more harm to the individual than drug use
[17]. Researchers were interested in enrolling patients
whose illicit drug use severity was equal to or exceeded
their alcohol use severity, yet ethical considerations
demanded that researchers appropriately address the
more severe problem. Both drug and alcohol risk levels
were determined for this set of patients using two vali-
dated and widely used brief screeners available in both
English and Spanish interview formats: a) the AUDIT —
Alcohol Use Disorders Identification Test [18], and b)
the DAST-10 — Drug Abuse Screening Test [19,20].
HEs computed AUDIT and DAST scores, and applied
standard cut-points to determine risk categories (i.e., low
risk, at risk, high risk, and severe risk). The AUDIT alco-
hol risk categories were based on Babor et al. [18] and in-
cluded no/low risk (score of 0–7), at risk (score of 8–15),
high risk (score of 16–19), and severe risk (score of
20–40). The DAST-10 categories were based on those
of the test’s developer [20] and included no/low risk
(score of 0), at risk (score of 1–2), high risk (score of 3–8),
and severe risk (score of 9–10). Patients whose alcohol
use risk category exceeded their drug use risk category
were given a brochure that described safe drinking limits
and were provided internet and community resources for
alcohol problems. Those patients whose drug use risk
category was equal to or higher than their alcohol risk
category were considered eligible, and were then asked
if they would like more information about the study.
Potential participants were offered $5 on the day of en-
rollment and baseline assessment, and $20 after com-
pletion of a 6-month follow-up interview.
Figure 1 presents a CONSORT diagram of the flow of
patients through the trial [15,21]. Eligibility and interest
in participating was assessed for over 18,000 patients.
About 95 percent of those approached were not eligibleprimarily because their drug use risk did not exceed
their alcohol use risk. Of the 988 eligible, 9.5 percent de-
clined to participate, and 19.4 percent did not finish the
consent process or did not provide the necessary contact
information because of interruptions for care from hos-
pital staff. The result was 700 patients enrolled in the
study.
Baseline procedures
An informed consent process was administered to inter-
ested, eligible participants. Using an interview format,
HEs then collected demographic information; five com-
ponents of the Addiction Severity Index Lite [22]; a driv-
ing and traffic safety measure that was immediately scored
into risk categories; and a drug avoidance self-efficacy
measure. Participants were then randomly assigned based
on last digit of their telephone number to Life Shift (even
number) or to Shift Gears (odd number), and a level of
motivational intervention matched to each participant’s
condition and risk level was delivered. Because the HE
delivered the type and level of intervention, he/she was
aware of the participant’s assigned condition.
Interventions
The Life Shift drug intervention and the Shift Gears driving/
traffic safety intervention were manual-driven, designed to
be of the same duration, and were available in English
and Spanish. Both had core SBIRT elements, which all
participants received, as well as adaptive elements that
allowed the HE to tailor the program based on the par-
ticipant’s needs and risk level [23]. Both interventions
began with the HE assessing the participant’s risk level.
Interventions were delivered in a non-judgmental manner
using a brochure to help communicate the short- and
long-term health, social, and legal effects. (For the Life
Shift intervention, drug-specific brochures were used
when marijuana, cocaine, and methamphetamine were the
drugs of choice; otherwise, a general drug use brochure
was used.) The participant’s motivation or readiness to
change, a construct based on the Transtheoretical Model
[24], was then assessed using a 4-point scale. The Life Shift
participants were asked, “How ready are you at the
present time to change your use of < specific drug > ?”
while the Shift Gears participants were asked, “How ready
are you at the present time to change your risky driving
behaviors?” Participants answered “not at all ready to
change”, “slightly ready”, “moderately ready”, or “very
ready to change”. The readiness information was used to
guide additional discussion about the participant’s drug
use (or risky driving/traffic behaviors). Together, the HE
and participant made a plan specific to the participant,
based on the discussion and recorded ideas on the work-
sheet on the back of the brochure. A core element of both
interventions, and SBIRT in general, was motivational
Figure 1 CONSORT diagram showing the flow of patients through the trial.
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change counseling [25,26]. More information about both
interventions is described below.
Life Shift drug use intervention
Based on DAST-10 categories resulting from standard
scoring procedures [20] and the MI process, participants
in the Life Shift group received one of three tracks tai-
lored to their specific risk category:
1. Brief intervention for at-risk individuals scoring 1
to 2 — Brief intervention with at-risk participants
was delivered on-site in the ED/trauma unit. This
interaction between the participant and HE included
feedback, exploring the participant’s ambivalence
about drug use and change, and a negotiation/
commitment to abstain or reduce use.
2. Brief treatment for high-risk individuals scoring 3 to
8 — In addition to the on-site brief intervention,
high-risk participants were offered 6 individual
sessions with a Life Shift substance use counselor
(a licensed therapist) over the phone. The sessions
incorporated principles of MI and cognitive-behavioral
therapy. The HE offered to make the first phone
appointment for the participant.3. Referral to treatment for severe-risk individuals
scoring 9 to 10 — In addition to the on-site brief
intervention and the offer of brief treatment phone
counseling, severe-risk participants were given a
list of local agencies that could provide further
assessment and support.
Shift Gears driving and traffic safety intervention
Participants assigned to the Shift Gears program re-
ceived an appropriate intervention for their specific risk
level, based on a modified version of the Driver Behavior
Questionnaire (DBQ) [27-29] adapted for our use, and
on their readiness to change. The DBQ is an assessment
tool designed to identify and classify driving behaviors
into specific categories. Levels of Shift Gears were two-
tiered instead of three-tiered, based on our formative
work that showed less variability in driving/traffic risk
than drug use risk. However, the intervention was of the
same duration (about 15–20 minutes for a brief inter-
vention) and included the same motivational elements
as Life Shift. The two tracks of intervention included:
1. Brief intervention for low- to at-risk individuals
scoring 0 to 15 — The brief intervention focused on
the mental and physical driving task, including a)
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dividing attention between two or more sources of
visual information, and b) external (e.g., cell phone
use, texting) and internal (e.g., road rage) conditions
that affect the driving task. To avoid overlap in
content of the Life Shift and Shift Gears interventions,
drunk and drugged driving was not a focus of the
control intervention. This interaction between
participant and the HE included feedback,
problem-solving, exploring the participant’s
ambivalence about risky driving and change, and a
negotiation/commitment to abstain or reduce risky
driving, traffic, or pedestrian behaviors.
2. Referral to treatment for high- to severe-risk
individuals scoring 16 to 26+ — In addition to the
on-site brief intervention, high- to severe-risk
participants received a referral list of free on-line or
in-person driving and traffic safety classes.
Cohort maintenance and follow-up assessment
procedures
Pairs of trained bilingual/bicultural MTs, different from
the HEs and blind to the participant’s condition, con-
ducted cohort maintenance activities (i.e., phone calls
and mailed postcards) and 6-month follow-up assess-
ments. Assessments were typically conducted at a con-
venient public place selected by the participant, usually
at a coffee house. The follow-up visit repeated most of
the baseline measures, and a hair sample was collected
for those participants reporting abstinence. A $20 incen-
tive at the end of the follow-up visit was provided. Three
participants had moved out of the vicinity; therefore,
MTs conducted these assessments over the telephone.
Measures
HEs used standardized instruments, such as the con-
densed version of the Addiction Severity Index (ASI-Lite),
to collect presumed intermediate variables targeted by the
intervention; driving and traffic safety attitudes and behav-
iors; and socio-demographic characteristics during the
baseline interview [22]. MTs collected these measures at
follow-up. Response cards and machine-scannable surveys
were used to facilitate data collection and processing.
Outcome measures
Past 30-day drug abstinence at follow-up
The primary outcome measure was self-reported, past 30-
day abstinence measured at 6-month follow-up, a dichot-
omous variable computed using ASI-Lite. The psychometric
properties of the ASI-Lite are similar to those of the longer
ASI [30], which is the most widely used assessment tool in
the addictions field. The ASI-Lite gathers quantitative infor-
mation (i.e., number of days in the past 30 days) about the
participant’s recent use of several broad types of illicit drugs(heroin, methadone, other opiates/analgesics, barbiturates,
other sedatives/hypnotics/tranquilizers, cocaine, amphet-
amines, cannabis, hallucinogens, and “other drugs”), includ-
ing alcohol [31,32].
A secondary outcome measure was biologically validated
drug use abstinence. Inaccuracies in self-reported drug use
post-treatment are likely to be high because of demand
characteristics and other factors [33,34]. Therefore, MTs
asked for a head hair sample during the follow-up inter-
view to assess past-month use from participants who
reported that they had abstained from all illicit drug use in
the past 30 days. Samples were collected and hair was seg-
mented to represent the last 30 days of drug use [35]. Hair
samples were tested for cocaine, benzoylecgonine, opiates,
oxycodone, methamphetamine, amphetamine, and canna-
binoids using ELISA (Immunalysis, Pomona, CA) with a
detection cut-off of 0.20 nanograms per milligram of hair.
Extracts that screened positive were forwarded for
confirmational analysis by gas chromatography–mass
spectrometry (GC-MS). GC-MS analysis identified and
quantified 17 drugs and metabolites: amphetamine, meth-
amphetamine, MDA, MDMA, cocaine, benzoylecgonine,
norcocaine, cocaethylene, methadone, codeine, morphine,
6-monoacetylmorphine (heroin metabolite), oxycodone,
oxymorphone, hydrocodone, hydromorphone, and me-
peridine. Instrumentation and methodology were previ-
ously published [36]. Cannabinoid results obtained by
ELISA were reported qualitatively. The drug analyses
conducted, while not comprehensive, tested for the
most common drugs of abuse in the County. When hair
analysis results were positive for drug use, the individ-
ual was considered non-abstinent.
Addiction severity index composite scores
Several secondary outcome variables were based on
composite scores measured by the ASI-Lite [22]. As
mentioned above, the ASI-Lite gathers quantitative in-
formation (i.e., number of days in the past 30 days)
about the participant’s recent use of several broad types
of illicit drugs. In addition, it assesses other areas of the
participant’s life commonly affected by substance use: a)
medical problems, b) psychiatric problems, and c) alco-
hol use. Composite scores to measure problem severity
were mathematically derived for the four ASI measures
by combining responses from each ASI-Lite problem
area using recommended scoring procedures [31]. Com-
posite scores range from 0 to 1, with higher scores indi-
cating greater severity of the problem.
Health-care utilization
The two hospital sites provided participant-level, health-
care utilization data from their cumulative patient data-
bases, which provided additional secondary outcomes.
Measures, assessed for the period of 6 months prior and
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included: a) the number of visits to the ED/trauma unit
in the past 6 months, excluding the current visit, b) the
number of hospitalizations in the past 6 months, and c)
the number of hospital days in the past 6 months. Only
one of the two sites was able to provide the last two
utilization measures.
Driving and traffic safety risk scores
To evaluate the specific effect of the SBIRT Life Shift
drug intervention in generating positive changes in drug
use beyond what attention alone might produce, all par-
ticipants completed driving and traffic safety attitude
and behavior measures at baseline and follow-up. Partic-
ipants in the driving safety attention-placebo control
group were expected to have greater changes in these
measures relative to the SBIRT drug use intervention
group. An 11-item measure, based partly on the DBQ
[27-29], was used to assess changes in driving risks (e.g.,
texting while driving) as well as general traffic and ped-
estrian risks (e.g., crossing the street against the light).
Participants were asked to indicate how often they per-
formed specific violations/errors based on a 5-point
scale ranging from 0 “never” to 5 “nearly all the time”. A
mean of the items was computed as an overall score.
The internal consistency (Cronbach’s alpha) for the
measure was .70.
Additional variables collected at baseline
Several variables were collected at baseline only to
characterize the sample, to ascertain risk levels for inter-
vention intensity, and to serve as covariates in analyses.
Sociodemographic variables collected by the HEs at
baseline included participants’ gender; age in years; race/
ethnicity using the categories Hispanic/Latino, White
non-Latino, African-American, and other; and annual
household income measured by six categories ranging
from less than $9,999 to $50,000 or more. A 4-item self-
efficacy scale was used to assess confidence in avoiding
drug use in four situations (e.g., when you’re feeling de-
pressed). This brief instrument has shown good validity
and reliability with drug users [37]. Items were answered
on a Likert scale ranging from 1 to 5, with higher mean
scores indicating greater confidence. The internal
consistency of the scale was .86. Finally, driving and traf-
fic safety risk scores were used to categorize participants
into two groups: low- to at risk, and high- to severe risk.
Analyses
Chi-square analyses and independent sample t-tests were
used to assess the comparability of Life Shift and Shift
Gears participants at baseline, and the degree to which
those lost to follow-up were different from those who
remained in the study. Abstinence outcomes were analyzedusing logistic regression and included site as a covariate.
Mixed-model analyses of variance procedures within a
general linear model framework were conducted on ASI
composite measures and health-care utilization to assess
intervention effects. Because ASI composite measures
often are not normally distributed, analyses with log-
transformed ASI composite scores and utilization data
were also conducted. The results did not differ from the
non-transformed analyses; consequently, results presented
are those of the original analyses. The group-by-time inter-
action was of particular interest because it is indicative of
differential group change. Site was included in all models
as a between-subjects factor. Initial tests indicated that
follow-up data for the quantitative self-reported outcomes
were not missing completely at random. Therefore, two
sets of analyses for the self-reported data were conducted:
a) complete-case analyses of 292 participants with longitu-
dinal data, and b) intention-to-treat analyses using multiple
imputation to deal with loss to follow-up (n = 694) [38].
Imputed outcome values were predicted from baseline
drug and alcohol risk levels, gender, age, income, and drug
avoidance self-efficacy; imputed values were possible for
only 694 participants because six individuals had too many
missing data values. Dichotomous abstinence measures at
follow-up were analyzed using generalized linear models
that controlled for site. Imputation was not possible for
categorical outcomes; therefore, analyses of the abstinence
outcome are presented for complete cases only. All ana-
lyses were conducted using SPSS version 20.
Sample
Participant characteristics
A total of 700 participants were enrolled, with 49.3 percent
(n = 346) assigned to the Life Shift group, and 50.7 percent
(n = 354) assigned to the Shift Gears group (see Figure 1).
Table 1 presents baseline characteristics of the sample
overall and by condition [15]. No significant differences
were found between the two groups on any of the baseline
characteristics examined. About three-fourths of the par-
ticipants were men. The average age was in the mid-
thirties. The sample was ethnically diverse, with one-third
being Latino. Sixty-five percent reported an annual income
of less than $10,000 per year. Severity of drug use var-
ied, with about 45 percent at high or severe risk.
Ninety-four percent were at relatively low risk for alco-
hol misuse (i.e., low risk or at risk), not surprisingly,
due to the eligibility criteria of greater drug use risk
than alcohol use risk. Marijuana was by far the most
common drug used (84%). About half of participants
were users of marijuana only. A measure of self-efficacy
for avoiding drugs was 3.2 on a 5-point scale, ranging
from low (1) to high (5) self-efficacy. Approximately 90
percent of participants were in the low- to at-risk level
for driving and traffic safety.
Table 1 Characteristics of Life Shift/Shift Gears
participants overall and by condition
Percent or mean (SD)
Characteristic Overall Life Shift Shift Gears
(N = 700) (N = 346) (N = 354)
Gender (%)
Male 75.4 76.2 74.6
Female 24.6 23.8 25.4
Age category (%)
18-20 9.3 10.7 7.9
21-24 13.2 13.6 12.7
25-34 27.1 29.6 24.6
35-44 17.5 16.6 18.4
45-54 22.1 19.5 24.6
55+ 10.9 10.1 11.6
Mean age in years 36.9 (13.2) 35.9 (13.3) 37.9 (13.0)
Race/Ethnicity (%)
Hispanic/Latino 33.1 32.5 33.7
African American 37.0 36.5 37.4
White 24.8 26.0 23.6
Other 5.2 5.0 5.3
Annual income (%)
Less than $9,999 65.1 64.2 66.1
$10,000 - $14,999 12.9 11.7 13.9
$15,000 - $24,000 8.6 8.1 9.0
$25,000 - $34,999 5.0 6.6 3.5
$35,000 - $49,000 4.0 3.9 4.1
$50,000+ 4.4 5.4 3.5
Patient location (%)
ED 83.5 84.3 82.6
Trauma 16.5 15.7 17.4
Interviewed in Spanish (%) 3.9 4.1 3.7
Drug risk category (%)a
At risk 55.1 55.0 55.2
High risk 41.1 40.6 41.7
Severe risk 3.8 4.4 3.2
Alcohol use risk category (%)b
Low risk 70.3 73.7 67.0
At risk 24.0 21.6 26.5
High risk 4.3 3.3 5.4
Severe risk 1.3 1.5 1.2
Type of drug used (%)c
Marijuana 84.4 87.5 81.4
Amphetamines 19.3 17.4 21.2
Cocaine 8.8 7.8 9.7
Heroin 7.8 6.1 9.6
Table 1 Characteristics of Life Shift/Shift Gears
participants overall and by condition (Continued)
Other opiates 7.4 7.6 7.3
User of Marijuana only (%) 49.6 51.6 47.7
Use of more than 1 substance
incl. alcohol (%)
49.9 47.9 51.9
Mean drug avoidance
self-efficacy score
3.2 (1.19) 3.2 (1.2) 3.3 (1.2)
Driving and traffic safety
risk category (%)
Low- and at risk 91.3 93.4 89.2
High- and severe risk 8.7 6.7 10.6
aBased on the Drug Abuse Screening Test — DAST-10 [19,20]. Risk categories
included at risk (score of 1–2), high risk (score of 3–8), and severe risk
(score of 9–10).
bBased on the Alcohol Use Disorders Identification Test — AUDIT [18]. Risk
categories included no/low risk (score of 0–7), at risk (score of 8–15), high risk
(score of 16–19), and severe risk (score of 20–40).
cMultiple drug use was possible. Therefore, the total percent exceeds 100%.
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The overall follow-up rate was 42 percent (292 of the
700 were followed successfully). Figure 1 presents the
reasons for loss to follow-up by condition. Analyses indi-
cated that dropout status was not related to condition,
site, gender, race/ethnicity, income, driving/traffic risk
scores, baseline alcohol use risk level, or the baseline
medical, psychiatric, or alcohol use composite scores.
However, younger people, those with more severe base-
line drug use, and those with lower baseline drug use
avoidance self-efficacy were more likely to be lost to
follow-up.
Results
Participation in hair sampling at follow-up
Thirty-one participants at follow-up reported being ab-
stinent from all drugs during the past 30 days. MTs col-
lected hair samples for verification from 14 of the 31
participants (8 Life Shift and 6 Shift Gears participants).
Of the 14 that provided hair samples, 10 were found to
be abstinent and four were non-abstinent. Hair samples
were not collected for the remaining 17 participants for
the following reasons: a) nine declined to provide a hair
sample at the time of follow-up, b) three were not avail-
able because they had moved out of the state and con-
ducted the interview with the MT by telephone, c) three
had insufficient body hair, and d) two failed to have hair
samples taken for unknown reasons. Missing collection
of hair among those reporting abstinence did not differ
by condition. Conservatively, all 17 were assumed to be
non-abstinent in the analysis of past 30-day abstinence.
Effects of intervention
As shown in Table 2, self-reported past 30-day abstin-
ence from all drug use assessed during the follow-up
Table 2 Outcomes of Life Shift/Shift Gears using complete cases (n=292) and imputed cases (n = 694)
Means (SE) or percent
Outcome Life Shift intervention Shift Gears control p value for group ×; time
interaction or Wald χ2
Baseline Follow-up Baseline Follow-up
Past 30 day drug abstinence at follow-up (%)b
Self-reported 12.5 (3.2) 12.0 (3.1) .888
Biologically validatedc 7.0 (2.5) 2.0 (1.2) .074
Self-reported drug use – ASI Composite Score (0-1)
Complete cases .059 (.008) .068 (.010) .055 (.007) .095 (.010) .035a
Imputed .070 (.005) .075 (.006) .068 (.006) .085 (.007) .124a
Medical problems – ASI Composite Score (0-1)
Complete cases .639 (.021) .176 (.038) .696 (.020) .280 (.036) .404a
Imputed .65 (.013) .219 (.023) .669 (.014) .248 (.024) .627a
Psychiatric problems – ASI Composite Score (0-1)
Complete cases .287 (.031) .250 (.029) .292 (0.27) .243 (.025) .734a
Imputed .264 (.017) .239 (.016) .272 (.017) .228 (.017) .404a
Alcohol use – ASI Composite Score (0-1)
Complete cases .127 (.018) .124 (.016) .106 (.017) .106 (.015) .888
Imputed .126 (.011) .115 (.009) .126 (.012) .112 (.010) .808
Past 6 mo. health care utilization
No. of ED visitsd .528 (.106) .828 (.129) .549 (.111) .806 (.135) .826a
No. of hospitaliz.e .196 (.094) .261 (.111) .146 (.099) .317 (.117) .479
No. of days hosp.e 1.26 (.607) 1.60 (643) 1.43 (.643) 2.56 (.681) .335a
Driving and traffic risk scores
Complete cases .975 (.068) .831 (.070) .840 (.064) .907 (.066) .057
Imputed 1.00 (.045) .935 (.042) .837 (.048) .897 (.045) .165
aSignificant time main effect, p < .05.
bImputation not available for dichotomous outcomes, therefore, analyses based on 292 complete cases.
cThose followed and reporting 0 drug use but who did not provide a hair sample for any reason; assumed to be nonabstinent.
dData available for 602 patients.
eSite 2 only; data available for 97 patients.
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Shift Gears, a non-significant difference (p = .888). When
results of hair analyses were applied, abstinence rates
were 7 percent for Life Shift and 2 percent for Shift
Gears; the difference between groups was not significant
(p = .074).
Table 2 presents mean ASI drug use composite scores
by condition and results of statistical tests of changes.
Of interest are the relatively low baseline drug use com-
posite scores in both groups (approximately .06 on a 0
to 1 scale). Among complete cases, the Life Shift inter-
vention group showed relatively small increases in ASI
composite scores for self-reported use of any drugs com-
pared to the Shift Gears attention-placebo control group.
The differential change resulted in a significant group-
by-time interaction (p = .035) in favor of Life Shift inter-
vention effectiveness, in addition to a time main effect.
An additional analysis indicated that the differentialgroup change in drug use scores did not differ for
marijuana-only users versus users of other drugs (data not
shown). When imputed data were analyzed, however, the
interaction was no longer statistically significant.
Psychiatric problems, and particularly medical prob-
lems, declined over time in both groups at about the
same rate, resulting in a statistically significant time
main effect that was found with complete cases and im-
puted data. Alcohol use showed no time main effect or
interaction. Considering health-care utilization out-
comes, there were no group-by-time interactions; how-
ever, both groups increased over time (time main effect)
in the number of ED visits and the number of hospital
days. Number of hospitalizations also increased in both
groups, but did not approach statistical significance.
Results of driving and traffic risk scores showed a mar-
ginally significant interaction effect (p = .057), with the
Life Shift intervention participants showing greater
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was unexpected insofar as those in the Shift Gears con-
dition received the intervention in reducing driving and
traffic risks, whereas the Life Shift group did not receive
that intervention.
Discussion and conclusions
This study found no support for the effectiveness of the
SBIRT approach for illicit drug use. The primary out-
come variable, past 30-day drug abstinence, was not sig-
nificant. Analyses of ASI drug use composite scores
using imputed data were also not significant.
Comparing our results to those of others is difficult
given the lack of comparable study designs, differences
in the types of drug users targeted, and other important
methodological differences. Bernstein and colleagues’
randomized trial of brief motivational intervention in
clinics for opioid and cocaine users is the most similar
to the present study in terms of design [13]. Those au-
thors reported a 4.6 percentage-point difference in bio-
logically validated past 30-day abstinence rates between
intervention and control groups at 6-month follow-up
[13], similar to the 5 percentage-point difference in ab-
stinence rates reported here. They also reported benefi-
cial effects of the brief intervention on ASI drug and
medical composite scores. Their results are in stark con-
trast to ours, insofar as we did not see reductions in ASI
drug scores in the SBIRT intervention group. Differences
in enrollment criteria, the racial/ethnic composition of
participants, the content/intensity of what the control
group received, and the type of drug users enrolled make
formal comparison between the two study results diffi-
cult. It is also noteworthy that the Bernstein study enrol-
lees had much higher ASI drug use scores at baseline
(.25 versus .06), and lower ASI medical scores (.56 versus
.67) than did our participants. Perhaps the benefits of the
SBIRT approach are more greatly realized among those at
higher addiction levels.
Our study sample differed from those reported else-
where in terms of their ASI scores. For example, the
drug use composite score in our sample of .056 is lower
than the score of .09 reported for a nationally represen-
tative sample of those in outpatient treatment programs
[32], and far lower than the score of .25 reported for opi-
oid/cocaine users [13]. These differences are not surpris-
ing given that the present study sample was not in
treatment; so one would expect them to have lower
composite scores. The current study had a large propor-
tion of marijuana-only users; to the degree that they
were less likely to perceive their drug use as a problem
due to changing societal norms, their drug use compos-
ite scores would be relatively low. Psychiatric problem
scores in the current sample, however, were almost twice
as high as those among patients undergoing outpatientdrug treatment [32], and medical problem scores were
24 percent higher than among opiate and cocaine users
[13]. These differences underscore the heterogeneity of
drug users in terms of their co-morbid mental health
and medical status, and underscore the importance of
addressing mental health and/or medical needs within a
population needing substance use treatment.
There was no evidence that the SBIRT drug interven-
tion had an effect on medical/ psychiatric problems, al-
cohol use, or health-care utilization. Although results
from other studies are mixed, our findings are in line
with a meta-analysis that found no statistically signifi-
cant effect of SBIRT interventions on health-care
utilization [39]. Furthermore, the U.S. Preventive Ser-
vices Task Force [40] reported that evidence is insuffi-
cient to demonstrate that psychosocial intervention
reliably improves non-drug use outcomes for largely
asymptomatic patients whose illicit drug use is detected
through screening. Time main effects for several of these
outcomes were observed in the present study, indicating
similar changes in both intervention and control groups.
For example, there were decreases in self-reported med-
ical and psychiatric problems often associated with drug
use, and increases in health-care utilization for both
groups. Although this pattern might seem paradoxical,
differences in the measures may partly explain the find-
ing. ASI medical and psychiatric problem scores targeted
problems in the past 30 days, whereas health-care
utilization measures covered a longer period of time
(past 6 months). Furthermore, participants’ medical and
psychiatric problems at baseline were likely relatively
high, insofar as they were currently patients in an ED
visiting for a medical problem. At follow-up, however,
there were no patients awaiting care. Researchers sug-
gest that patients may no longer have been troubled by
their previous medical problems, and therefore, their
problem scores were lower.
Despite cohort maintenance activities, a high dropout
rate was a limitation of the study. In the present study,
populations more likely to be lost to follow-up included
younger people, individuals with more severe baseline
drug use, and those with lower baseline drug use avoid-
ance self-efficacy. High dropout is a reported problem in
many drug use studies, although other studies similar to
the present one have achieved high follow-up rates
[11,13]. Low participation in hair collection for confirm-
ing drug abstinence was also a limitation. Another pos-
sible limitation is related to using hair samples to
confirm self-reported drug use at follow-up, but not at
baseline. Participants were expected to have accurate
disclosure at admission into the study [16,41], although
others have reported that individuals may report drug
use at baseline that is not confirmed [13]. In addition,
because the HE delivered the type and level of
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assigned condition, so some bias may have been intro-
duced. However, measurement staff members were blind
to the participants’ conditions. Finally, a small sample
size (n = 97) for some analyses was also a problem.
The methodology of the study has many strengths, in-
cluding its minimal exclusion criteria. The decision to
include participants who were using an assortment of
substances and multiple substances was made for both
scientific and clinical reasons. Recruitment of varied and
polydrug users in research trials has been advocated by
experts in the field of substance use disorder research as
a “real world” test of an approach, and as a means to
bridge the gap between research and practice [42]. The
use of an attention-placebo control group is also a
strength, as it allowed us to test the rival hypothesis that
improvement in drug use occurred because of the partic-
ipant’s expectations or the attention received, rather
than from the SBIRT itself [43]. Unexpectedly, the
SBIRT group tended to improve more than the placebo
group on the measure related to driving and traffic
safety. The SBIRT drug use intervention may have been
more salient or interesting than the attention-placebo
control intervention, bringing about changes in a variety
of health and safety areas among those participants who
received it. Attempted biochemical validation of reports
of abstinence, a multiethnic sample, and rigorous model-
ing of missing data are additional strengths.
The null results of the present study are disappointing,
yet it is premature to conclude that SBIRT cannot work
for drug use. Alternative explanations, such as those re-
lated to intervention implementation and measurement
may have obfuscated SBIRT’s effects. Future studies are
needed to rule out alternative explanations and add to
the knowledge about SBIRT effectiveness for drug use.
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